Oppenheimer Reiterates Perform Rating on Rhythm Pharmaceuticals (RYTM)

November 4, 2026 6:33 AM EST Send to a Friend
Oppenheimer analyst Leland Gershell reiterated a Perform rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented: "3Q26 Imcivree sales of $92.1M ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login